Related Experiment Videos
CpG methylation within the 5' regulatory region of the BRCA1 gene is tumor specific and includes a putative CREB
D N Mancini1, D I Rodenhiser, P J Ainsworth
1London Health Sciences Centre, Department of Paediatrics at the University of Western Ontario, Canada.
Abstract:
Breast cancer is a genetic disease arising from a series of germ-line and/or somatic DNA changes in a variety of genes, including BRCA1 and BRCA2. DNA modifications have been shown to occur by a number of mechanisms that include DNA methylation. In some cases, the aberrant methylation of CpGs within 5' regulatory regions has led to suppression of gene activity. In this report we describe a variation in the pattern of DNA methylation within the regulatory region of the BRCA1 gene. We found no evidence of methylation at CpGs within the BRCA1 promoter in a variety of normal human tissues. However, screening of a series of randomly sampled breast carcinomas revealed the presence of CpG methylation adjacent to the BRCA1 transcription start site. One such methylated CpG occurs at a putative CREB (cAMP-responsive element binding) transcription factor binding site in the BRCA1 promoter. Gelshift assays with methylated and unmethylated BRCA1/CREB binding site oligonucleotides demonstrate that this site is sensitive to site-specific CpG methylation. These data suggest that aberrant DNA methylation at regulatory sequences in the BRCA1 locus may play a role in the transcriptional inactivation of the BRCA1 gene within subclones of breast tumors. This study represents the first evidence suggesting a role for DNA methylation in the transcriptional inactivation of the BRCA1 in human breast cancer.
Insights
Aberrant DNA methylation in the BRCA1 gene promoter may silence this tumor suppressor in breast cancer. This study provides the first evidence linking DNA methylation to BRCA1 inactivation in human breast tumors.
Area of Science:
- Oncology
- Epigenetics
- Molecular Biology
Background:
- Breast cancer involves genetic alterations, including in BRCA1 and BRCA2 genes.
- DNA methylation is a key epigenetic mechanism that can alter gene activity.
- Aberrant methylation in regulatory regions can suppress gene expression.
Purpose of the Study:
- To investigate DNA methylation patterns in the BRCA1 gene promoter in breast cancer.
- To determine if BRCA1 promoter methylation correlates with gene silencing in breast tumors.
Main Methods:
- Analysis of DNA methylation in the BRCA1 promoter region of normal tissues and breast carcinomas.
- Identification of methylated CpGs within the BRCA1 promoter, including a CREB binding site.
- Electrophoretic mobility shift assays (EMSA) to assess the impact of methylation on transcription factor binding.
Main Results:
- No CpG methylation was detected in the BRCA1 promoter of normal human tissues.
- CpG methylation was observed adjacent to the BRCA1 transcription start site in breast carcinomas.
- Methylation of a specific CpG site within a CREB binding site reduced transcription factor binding.
Conclusions:
- Aberrant DNA methylation in the BRCA1 promoter may contribute to BRCA1 transcriptional inactivation in breast cancer.
- This study presents the initial evidence for DNA methylation's role in BRCA1 silencing in human breast cancer.
- Epigenetic modifications like DNA methylation represent a potential mechanism driving breast cancer development.